Literature DB >> 20359629

Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Elaine M Sloand1, A J Barrett.   

Abstract

Laboratory evidence and clinical evidence suggest that some patients with myelodysplastic syndrome (MDS) have immunologically mediated disease. This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20359629      PMCID： PMC3793398          DOI： 10.1016/j.hoc.2010.02.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  63 in total

Review 1.  Role of the WT1 gene in Wilms' tumour.

Authors:  D A Haber; D E Housman
Journal:  Cancer Surv       Date:  1992

2.  Mapping and characterization of 129 cosmids on human chromosome 11p.

Authors:  K M Call; C Y Ito; C Lindberg; A Memisoglu; C Petrou; T Glaser; C Jones; D E Housman
Journal:  Somat Cell Mol Genet       Date:  1992-09

3.  Treatment of bone marrow aplasia by mismatched bone marrow transplantation after conditioning with antilymphocyte globulin--long-term results.

Authors:  G Mathé; L Schwarzenberg
Journal:  Transplant Proc       Date:  1976-12       Impact factor: 1.066

4.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

5.  Results of immunosuppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplant (EGBMT).

Authors:  E Gluckman; A Devergie; A Poros; P Degoulet
Journal:  Br J Haematol       Date:  1982-08       Impact factor: 6.998

6.  Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Elaine M Sloand; Olga Nunez; Carol Boss; Neal S Young
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

Review 7.  WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.

Authors:  Daniela Cilloni; Giuseppe Saglio
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

8.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.

Authors:  M Stadler; U Germing; K-O Kliche; K M Josten; R Kuse; W-K Hofmann; H Schrezenmeier; J Novotny; O Anders; H Eimermacher; W Verbeek; H-H Kreipe; H Heimpel; C Aul; A Ganser
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

9.  Measurement of serum cytokine levels in patients with myelodysplastic syndromes.

Authors:  G E Verhoef; P De Schouwer; J L Ceuppens; J Van Damme; W Goossens; M A Boogaerts
Journal:  Leukemia       Date:  1992-12       Impact factor: 11.528

10.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.

Authors:  J Maciejewski; C Selleri; S Anderson; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113
View more
  9 in total

1.  Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes.

Authors:  Aziz Nazha; David Seastone; Tom Radivoyevitch; Bartlomiej Przychodzen; Hetty E Carraway; Bhumika J Patel; Jennifer Carew; Hideki Makishima; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2015-08-13       Impact factor: 9.941

Review 2.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

3.  Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.

Authors:  Sheryl M Gough; Yang Jo Chung; Peter D Aplan
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

4.  High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet's Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet's Disease Database and Comparison with the Literature.

Authors:  Yan Shen; Hai-Fen Ma; Dan Luo; Jian-Fei Cai; Jun Zou; Jian-Long Guan
Journal:  Biomed Res Int       Date:  2018-04-24       Impact factor: 3.411

5.  CAISC: A software to integrate copy number variations and single nucleotide mutations for genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing.

Authors:  Jeerthi Kannan; Liza Mathews; Zhijie Wu; Neal S Young; Shouguo Gao
Journal:  BMC Bioinformatics       Date:  2022-03-21       Impact factor: 3.169

6.  Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes.

Authors:  Adam W Mailloux; Pearlie K Epling-Burnette
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

7.  A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.

Authors:  Masatsugu Endo; Akira Sekikawa; Takehiko Tsumura; Takanori Maruo; Yukio Osaki
Journal:  Am J Case Rep       Date:  2015-11-21

8.  Immunological derangement in hypocellular myelodysplastic syndromes.

Authors:  B Serio; Am Risitano; V Giudice; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2014-02-04

Review 9.  Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review).

Authors:  Hana Votavova; Monika Belickova
Journal:  Int J Oncol       Date:  2021-12-27       Impact factor: 5.650
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.